This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Bristol-Myers (BMY) Q4 Earnings Beat Estimates
by Indrajit Bandyopadhyay
Bristol-Myers (BMY) beat estimates on both counts.
Merck vs. Sanofii: Which Stock Is Better Pre-Q4 Earnings?
by Zacks Equity Research
With Merck and Sanofi scheduled to report on Feb 2 and Feb 27, respectively, this may be a good time to figure out which of these is a better stock.
Should You Sell Bristol-Myers Squibb (BMY) Before Earnings?
by Zacks Equity Research
Bristol-Myers Squibb (BMY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.
Will Bristol-Myers' (BMY) Q4 Earnings Exceed Expectations?
by Zacks Equity Research
Bristol-Myers' (BMY) Opdivo is likely to play an instrumental role in driving fourth-quarter 2017 results.
Seattle Genetics Adcetris Performs Well Despite Competition
by Zacks Equity Research
Seattle Genetics (SGEN) is witnessing robust growth for its sole marketed product, Adcetris. However, over dependence on the same is a concern amid rising competition.
FDA Nod for QIAGEN's JAK2 Test Boosts Molecular Diagnostic
by Zacks Equity Research
QIAGEN (QGEN) strives to enhance Molecular Diagnostic segment, which was the highest revenue grosser in the last reported quarter.
Infinity Provides Update on Lead Candidate, Issues 2018 View
by Zacks Equity Research
Infinity (INFI) announces the achievement of some development milestones for its lead pipeline candidate- IPI-549 and issued financial guidance for 2018.
Seattle Genetics' Adcetris Gets EU Nod for Label Expansion
by Zacks Equity Research
European Commission extend the current conditional marketing authorization for an expanded indication of Adectris of Seattle Genetics (SGEN) and partner Takeda.
BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall
by Zacks Equity Research
Shares of BioCryst Pharmaceuticals (BCRX) and Idera Pharmaceuticals (IDRA) plunge following the announcement of their merger.
Healthcare ETFs to Watch As Q4 Earnings Unfold
by Sweta Killa
With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 3% in the fourth quarter, suggesting some upside for healthcare ETFs.
Bristol-Myers (BMY) Reports Data from CheckMate-142 Study
by Zacks Equity Research
Bristol-Myers (BMY) announces new data from a cohort of the phase II CheckMate -142 study evaluating Opdivo (nivolumab) and Yervoy (ipilimumab).
Pharma Stock Roundup: Merck's Keytruda Shines in Study, Priority Review for Kymriah Label Expansion
by Arpita Dutt
Focus this week was on Merck's (MRK) data on Keytruda as well as Novartis's updates on Kymriah and its biosimilar efforts.
Exelixis, Ipsen Report Positive Results on Lead Cancer Drug
by Zacks Equity Research
Exelixis (EXEL) and Ipsen announce detailed results from the late stage study of lead drug Cabometyx in patients with previously treated advanced HCC.
Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference
by Arpita Dutt
Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.
Key Takeaways from Pfizer & 3 Other Drug Stocks at Healthcare Conference
by Arpita Dutt
Here is a look at key takeaways from presentations made by four major pharma and biotech stocks including Pfizer (PFE) at the annual J.P. Morgan healthcare conference.
Exelixis Amends Cabozantinib-Tecentriq Phase Ib Trial
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced an amendment to the protocol for the phase Ib trial of cabozantinib combined with Tecentriq whereby there will be four new expansion cohorts to the trial.
Seattle Genetics' Adcetris sBLA Gets FDA Priority Review
by Zacks Equity Research
Seattle Genetics' supplemental Biologics License Application for the label expansion of its lymphoma drug, Adcetris, was accepted by the FDA and granted priority review.
4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio
by Zacks Equity Research
Celldex stock has been performing well for the last six months and the momentum is likely to continue in the near term.
Pharma Stock Roundup: Roche, MNK Announce Acquisition Agreements, Regulatory Updates from Novartis
by Arpita Dutt
Although it's been a relatively slow week, two acquisition deals were announced with Roche (RHHBY) saying it will acquire Ignyta while Mallinckrodt will buy Sucampo.
Clovis Up More Than 50% in 2017: What's Driving the Stock?
by Zacks Equity Research
Clovis Oncology (CLVS) stock is rapidly gaining momentum. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.
Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018?
by Zacks Equity Research
Exelixis (EXEL) had a phenomenal run in 2017 driven by sales of Cabometyx and we expect the momentum to continue in 2018 on the back of the label expansion of the drug.
Merck's Diabetes Drugs Get FDA Nod as Adjunct Therapies
by Zacks Equity Research
Merck's (MRK) three diabetes drugs get FDA approval as adjunct treatment to diet and exercise to improve glycemic control in patients with diabetes mellitus.
Portola's (PTLA) AndexXa BLA Review Period Extended by FDA
by Zacks Equity Research
The FDA extends the review period of Portola's (PTLA) biologics license application for AndexXa by 90 days. Its response is now deferred to May 4, 2018 instead of the earlier Feb 3 deadline.
Cancer Space Update: FDA Approves Label Expansion of 4 Drugs
by Zacks Equity Research
The FDA has approved label expansion of four different drugs from Roche, Exelixis, Pfizer and Bristol-Myers. However, Celgene faced a setback as Revlimid failed in a phase III study.
Pharma Stock Roundup: Aerie's Rhopressa Approved, Label Expansion for BMY, Pfizer Drugs
by Arpita Dutt
This week's pharma sector highlights include the FDA approval of Aerie's (AERI) Rhopressa as well as the label expansion of Pfizer's Bosulif and Bristol-Myers's Opdivo.